BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2720660)

  • 1. Nuclear distribution of the Ki-67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cells.
    van Dierendonck JH; Keijzer R; van de Velde CJ; Cornelisse CJ
    Cancer Res; 1989 Jun; 49(11):2999-3006. PubMed ID: 2720660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [In situ determination of the Ki-67 growth fraction (Ki-67 GF) in human tumors (studies in breast cancer)].
    Lellé RJ
    Acta Histochem Suppl; 1990; 39():109-24. PubMed ID: 2080254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification and topographical description of Ki-67 antibody labelling during the cell cycle of normal fibroblastic (MRC-5) and mammary tumour cell lines (MCF-7).
    Guillaud P; du Manoir S; Seigneurin D
    Anal Cell Pathol; 1989 Feb; 1(1):25-39. PubMed ID: 2488698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-cycle-related staining patterns of anti-proliferating cell nuclear antigen monoclonal antibodies. Comparison with BrdUrd labeling and Ki-67 staining.
    van Dierendonck JH; Wijsman JH; Keijzer R; van de Velde CJ; Cornelisse CJ
    Am J Pathol; 1991 May; 138(5):1165-72. PubMed ID: 1673821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can transforming growth factor-beta1 and retinoids modify the activity of estradiol and antiestrogens in MCF-7 breast cancer cells?
    Czeczuga-Semeniuk E; Anchim T; Dziecioł J; Dabrowska M; Wołczyński S
    Acta Biochim Pol; 2004; 51(3):733-45. PubMed ID: 15448735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Determination of the growth fraction using monoclonal antibody Ki-67 in breast cancers].
    Lellé RJ; Heidenreich W; Borsi C; Stauch G; Gerdes J
    J Gynecol Obstet Biol Reprod (Paris); 1988; 17(4):485-9. PubMed ID: 3209828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.
    Gerdes J; Lemke H; Baisch H; Wacker HH; Schwab U; Stein H
    J Immunol; 1984 Oct; 133(4):1710-5. PubMed ID: 6206131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen.
    Reddel RR; Murphy LC; Hall RE; Sutherland RL
    Cancer Res; 1985 Apr; 45(4):1525-31. PubMed ID: 3978620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell cycle analysis of estrogen stimulation and antiestrogen inhibition of growth of the human breast cancer cell line MCF-7.
    Lykkesfeldt AE; Larsen JK; Christensen IJ
    Breast Cancer Res Treat; 1986; 7 Suppl():S83-90. PubMed ID: 3742066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of surface antigen expression per cell of human osteogenic sarcoma cells by fluorescence-labelled monoclonal antibodies.
    Rytwiński K
    Arch Immunol Ther Exp (Warsz); 1984; 32(6):649-58. PubMed ID: 6598741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect on growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice.
    Brünner N; Bronzert D; Vindeløv LL; Rygaard K; Spang-Thomsen M; Lippman ME
    Cancer Res; 1989 Mar; 49(6):1515-20. PubMed ID: 2924304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of tamoxifen on potential doubling time of human breast cancer cell line determined by image cytometry of double fluorescent BrdU and DNA labeling.
    Rostagno P; Moll JL; Birtwisle-Peyrottes I; Ettore F; Lagrange JL; Gioanni J; Caldani C
    Anticancer Res; 1994; 14(5A):2025-32. PubMed ID: 7531416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of pharmacological concentrations of estrogens on proliferation and cell cycle kinetics of human breast cancer cell lines in vitro.
    Reddel RR; Sutherland RL
    Cancer Res; 1987 Oct; 47(20):5323-9. PubMed ID: 3652038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell cycle progression and phenotypic modification of Ki67 antigen-negative G1- and G2-phase cells in phorbol ester-treated Molt-4 human leukemia cells.
    Tsurusawa M; Fujimoto T
    Cytometry; 1995 Jun; 20(2):146-53. PubMed ID: 7664625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of estrogen and progesterone receptors and the dissociated regulation of growth and progesterone receptor stimulation by estrogen in MDA-MB-134 human breast cancer cells.
    Reiner GC; Katzenellenbogen BS
    Cancer Res; 1986 Mar; 46(3):1124-31. PubMed ID: 3943090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibody identification and characterization of a Mr 43,000 membrane glycoprotein associated with human breast cancer.
    Edwards DP; Grzyb KT; Dressler LG; Mansel RE; Zava DT; Sledge GW; McGuire WL
    Cancer Res; 1986 Mar; 46(3):1306-17. PubMed ID: 3510721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of recombinant human leukocyte interferons on cell surface antigen expression.
    Greiner JW; Fisher PB; Pestka S; Schlom J
    Cancer Res; 1986 Oct; 46(10):4984-90. PubMed ID: 2944575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ki-67 antigen, a cell cycle and tumor growth marker].
    Seigneurin D; Guillaud P
    Pathol Biol (Paris); 1991 Dec; 39(10):1020-8. PubMed ID: 1666669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of spatial configuration of carcinoma cell populations on the expression of a tumor-associated glycoprotein.
    Horan Hand P; Colcher D; Salomon D; Ridge J; Noguchi P; Schlom J
    Cancer Res; 1985 Feb; 45(2):833-40. PubMed ID: 3881173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase.
    Osborne CK; Boldt DH; Clark GM; Trent JM
    Cancer Res; 1983 Aug; 43(8):3583-5. PubMed ID: 6861130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.